Pharma Industry News

Novartis hits targets in late-stage QMF149 asthma trial

The once-daily, fixed-dose treatment demonstrated significant improvements in lung function and asthma control.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]